Sign Up for a Free Account
  • Updated 10.05.2021
  • Released 07.06.1999
  • Expires For CME 10.05.2024

Glatiramer acetate


Historical note and terminology

Glatiramer acetate, formerly called copolymer-1, is one of a series of polypeptide preparations developed to stimulate myelin basic protein, a natural component of the myelin sheath. Myelin basic protein suppresses experimental allergic encephalomyelitis (the animal model of multiple sclerosis); a better suppression effect was demonstrated by the use of a synthetic basic copolymer (27). This provided the rationale for the use of copolymer in multiple sclerosis. Glatiramer acetate was developed for commercial use, and results of the first clinical trial were published in 1987. The United States Food and Drug Administration approved it in 1996 for use in multiple sclerosis patients.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125